High mobility group box 1 and its role in cervical cancer

doi:10.3760/cma.j.issn.1673422X.2017.03.020

Abstract

Abstract: Extracellular high mobility group box 1 (HMGB1) can cause persistent inflammation via related receptors and signal pathways such as receptor for advanced glycation endproduct, Tolllike receptors and chemokines 12, which results in tumorigenesis. In patients with cervical cancer, the expression of HMGB1 increases with the rising of malignant grade. HMGB1 participates in the genesis and development, invasion and metastasis of cancer through multiple processes. The expression of HMGB1 is inhibited by RNA interference, thus affects the invasion and migration of cervical cancer cell, which provides a new concept for the development of antineoplastic agents.

Key words: HMGB1 protein, Uterine cervical neoplasms, Inflammation, Antineoplastic agents

Chen Gang, Zhuang Fangcheng. High mobility group box 1 and its role in cervical cancer[J]. Journal of International Oncology, 2017, 44(3): 235-238.

References

［1］ Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease［J］. Mol Aspects Med, 2014, 40: 1-116. DOI: 10.1016/j.mam.2014.05.001. ［2］ Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases［J］. Diagnostics (Basel), 2015, 5(2): 219-253. DOI: 10.3390/diagnostics5020219. ［3］ Lee SA, Kwak MS, Kim S, et al. The role of high mobility group box 1 in innate immunity［J］. Yonsei Med J, 2014, 55(5): 1165-1176. DOI: 10.3349/ymj.2014.55.5.1165. ［4］ Rabadi MM, Xavier S, Vasko R, et al. Highmobility group box 1 is a novel deacetylation target of Sirtuin1［J］. Kidney Int, 2015, 87(1): 95-108. DOI: 10.1038/ki.2014.217. ［5］ Beyer C, Pisetsky DS. Modeling nuclear molecule release during in vitro cell death［J］. Autoimmunity, 2013, 46(5): 298-301. DOI: 10.3109/08916934.2012.750297. ［6］ Spencer DM, Mobarrez F, Wallén H, et al. The expression of HMGB1 on microparticles from Jurkat and HL60 cells undergoing apoptosis in vitro［J］. Scand J Immunol, 2014, 80(2): 101-110. DOI: 10.1111/sji.12191. ［7］ Yamamoto K, Murata H, Putranto EW, et al. DOCK7 is a critical regulator of the RAGECdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells［J］. Oncol Rep, 2013, 29(3): 1073-1079. DOI: 10.3892/or.2012.2191. ［8］ Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumorspecific immune response［J］. Cancer Res, 2011, 71(14): 4821-4833. DOI: 10.1158/00085472.CAN110950. ［9］ Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer［J］. Annu Rev Immunol, 2010, 28: 367-388. DOI: 10.1146/annurev.immunol.021908.132603. ［10］ Tsung A, Tohme S, Billiar TR. Highmobility group box1 in sterile inflammation［J］. J Intern Med, 2014, 276(5): 425-443. DOI: 10.1111/joim.12276. ［11］ Liu Y, Yan W, Tohme S, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Tolllike receptor 9［J］. J Hepatol, 2015, 63(1): 114-121. DOI: 10.1016/j.jhep.2015.02.009. ［12］ Nagasawa T. CXCL12/SDF1 and CXCR4［J］. Front Immunol, 2015, 6: 301. DOI: 10.3389/fimmu.2015.00301. eCollection 2015. ［13］ UtoKonomi A, McKibben B, Wirtz J, et al. CXCR7 agonists inhibit the function of CXCL12 by downregulation of CXCR4［J］. Biochem Biophys Res Commun, 2013, 431(4): 772776. DOI: 10.1016/j.bbrc.2013.01.032. ［14］ Schiraldi M, Raucci A, Muoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4［J］. J Exp Med, 2012, 209(3): 551-563. DOI: 10.1084/jem.20111739. ［15］ Kew RR, Penzo M, Habiel DM, et al. The IKKαdependent NFκB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1［J］. J Immunol, 2012, 188(5): 2380-2386. DOI: 10.4049/jimmunol.1102454. ［16］ Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation［J］. Proc Natl Acad Sci USA, 2014, 111(8): 3068-3073. DOI:10.1073/pnas.1316925111. ［17］ Wagner KU, Schmidt JW. The two faces of Janus kinases and their respective STATs in mammary gland development and cancer［J］. J Carcinog, 2011, 10: 32. DOI: 10.4103/14773163.90677. ［18］ Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis［J］. Cancer Res, 2012, 72(8): 1996-2005. DOI: 10.1158/00085472.CAN112291. ［19］孙小云, 张旭艳, 闫雪, 等. 宫颈癌组织中HMGB1、Notch1的表达及相关性［J］. 山东医药, 2015, 55(10): 30-32. DOI: 10.3969/j.issn.1002266X.2015.10.010. ［20］ Ohmori H, Luo Y, Kuniyasu H. Nonhistone nuclear factor HMGB1 as a therapeutic target in colorectal cancer［J］. Expert Opin Ther Targets, 2011, 15(2): 183-193. DOI: 10.1517/14728222.2011.546785. ［21］赵灵, 蔡红兵, 江大琼. 高迁移率族蛋白B1和基质金属蛋白酶9在宫颈鳞癌中的表达及其临床意义［J］. 武汉大学学报: 医学版, 2010, 31(3): 343-346. DOI: 10.14188/j.16718852.2010.03.029. ［22］ Sparatore B, Patrone M, Passalacqua M, et al. Activation of A431 human carcinoma cell motility by extracellular highmobility group box 1 protein and epidermal growth factor stimuli［J］. Biochem J, 2005, 389(Pt 1): 215-221. DOI: 10.1042/BJ20050053. ［23］李妍, 郝权. 高迁移率族蛋白1和肿瘤相关巨噬细胞与宫颈癌淋巴管密度的相关性研究［J］. 中国肿瘤临床, 2014, 41(4): 222-226. DOI: 10.3969/j.issn.10008179.20131738. ［24］ Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA211, and CEA levels［J］. Croat Med J, 2009, 50(5): 455-464. ［25］ Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1related pathologies［J］. Pharmacol Ther, 2014, 141(3): 347-357. DOI:10.1016/j.pharmthera.2013.11.001. ［26］ Arumugam T, Ramachandran V, Gomez SB, et al. S100Pderived RAGE antagonistic peptide reduces tumor growth and metastasis［J］. Clin Cancer Res, 2012, 18(16): 4356-4364. DOI: 10.1158/10780432.CCR120221. ［27］邱媛媛, 郝权, 田菁, 等. RNA干扰抑制HMGB1基因表达对宫颈癌HeLa细胞生物学行为的影响［J］. 中国癌症杂志, 2010, 20(10): 739-744. ［28］ Feng L, Wu J. Effect of expression of high mobility group box1 inhibited by small hairpin RNA on the invasion and migration of human endometrial carcinoma HEC1A cells［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(1): 36-42. DOI: 10.11817/j.issn.16727347.2014.01.007. ［29］ Wu R, Wu J. Inhibition on the proliferation of human endometrial cancer cells by RNAi inhibiting HMGB1 gene expression and its possible molecular mechanism［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(7): 673-680. DOI: 10.11817/j.issn.16727347.2014.07.004.

[1]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[3]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[4]	He Guangsi, Wang Jun, Feng Mengmeng. Predictive value of inflammatory markers of peripheral blood cells on prognosis in the advanced non-small cell lung cancer with immune therapy [J]. Journal of International Oncology, 2023, 50(6): 321-327.
[5]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[6]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[7]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[8]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[9]	Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 568-571.
[10]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[11]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[12]	Yuan Chenyang, Zhou Juying. Research progress on prognostic factors of cervical cancer [J]. Journal of International Oncology, 2022, 49(5): 307-313.
[13]	Liu Yonghong, Xue Lingbo, Bai Yang, Jin Jian, Zang Chunxia, Zhang Bo, Li Jie. Predictive value of systemic inflammation response index before treatment for pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy [J]. Journal of International Oncology, 2022, 49(4): 210-215.
[14]	Xu Lu, Long Jinhua, Jin Feng, Wu Weili. Clinical significance of expression of tumor immunogenic cell death related molecules [J]. Journal of International Oncology, 2022, 49(2): 106-110.
[15]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.